ArticleJournal of cheminformatics2025
Improving route development using convergent retrosynthesis planning.
Article in Journal of cheminformatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Enhancing biocatalytic retrosynthesis with a graph-to-graph model.Chemical science · 2026Article
- Advanced machine learning for innovative drug discovery.Journal of cheminformatics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Retrosynthesis consists of recursively breaking down a target molecule to produce a synthesis route composed of readily accessible building blocks. In recent years, computer-aided synthesis planning methods have allowed a greater exploration of potential synthesis routes, combining state-of-the-art machine-learning methods with chemical knowledge. However, these methods are generally developed to produce individual routes from a singular product to a set of proposed building blocks and are not designed to leverage potential shared paths between targets. These methods do not necessarily encompass real-world use cases in medicinal chemistry, where one seeks to synthesize sets of target compounds in a library mode, looking for maximal convergence into a shared retrosynthetic path going via advanced key intermediate compounds. Using a graph-based processing pipeline, we explore Johnson & Johnson Electronic Laboratory Notebooks (J&J ELN) and publicly available datasets to identify complex routes with multiple target molecules sharing common intermediates, producing convergent synthesis routes. We find that over 70% of all reactions are involved in convergent synthesis, covering over 80% of all projects in the case of J&J ELN data. Scientific contributionWe introduce a novel planning approach to develop convergent synthesis routes, which can search multiple products and intermediates simultaneously guided by state-of-the-art machine learning single-step retrosynthesis models, enhancing the overall efficiency and practical applicability of retrosynthetic planning. We evaluate the multi-step synthesis planning approach using the extracted convergent routes and observe that solvability is generally high across those routes, being able to identify a convergent route for over 80% of the test routes and showing an individual compound solvability of over 90%. We find that by using a convergent search approach, we can synthesize almost 30% more compounds simultaneously for J&J ELN as compared to using an individual search, while providing an increased use of common intermediates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.